Goldman Sachs gives Tempus AI (TEM.US) a "Neutral" rating for the first time: Diagnostic business awaits reimbursement dividends, while data contracts enter a "verification phase".

Zhitong Finance APP has learned that Goldman Sachs has released a research report initiating coverage on Tempus AI (TEM.US) with a "Neutral" rating and a target price of $75. Based on the latest share price of $78.03, this implies about 4% downside potential. This assessment is not considered pessimistic—the reimbursement catalysts for the diagnostics business are quite specific in the near term; however, contract renewals with major clients in the data business remain a question mark hanging over the valuation.